Nodular Lymphocyte-Predominant B-cell Lymphoma (formerly NLPHL) · line 1 · Rituximab monotherapy (375 mg/m² weekly × 4, then maintenance)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-RITUXIMAB-MONO |
| ID | IND-NLPBL-1L-RITUXIMAB-MONO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NLPBL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB. Alternative до ISRT для early-stage NLPBL коли RT не preferred.
Used By
Algorithms
ALGO-NLPBL-1L- ALGO-NLPBL-1L